Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
voxalatamab
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Voxalatamab (JNJ-63898081) is a humanized bispecific antibody designed to target both prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T cells. By binding simultaneously to PSMA and CD3, it acts as a bridge that redirects T cells to attack PSMA-expressing cancer cells, primarily in prostate cancer. The drug is being developed by Janssen Research & Development and was originally co-developed with Genmab. Its mechanism of action involves antibody-dependent cell cytotoxicity and stimulation of T lymphocytes for anti-tumor activity. Voxalatamab has been evaluated in phase 1 clinical trials for metastatic castration-resistant prostate cancer (mCRPC) and renal cell carcinoma (kidney cancer), particularly in patients who have progressed after standard therapies[1][2][3][4][5].
- Other names
- voxalatamabJNJ-63898081JNJ63898081JNJ 63898081JNJ-081JNJ081JNJ 081
02
Targets
CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on voxalatamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on voxalatamab.